Gwen Melincoff
Director/Board Member at GAIN THERAPEUTICS, INC.
Net worth: 575 610 $ as of 30/03/2024
Profile
Gwen A.
Melincoff currently works at Collegium Pharmaceutical, Inc., as Independent Director from 2017, Soleno Therapeutics, Inc., as Independent Director from 2019, Protalix Biotherapeutics, Inc., as Independent Director from 2019, Vodia Capital LLC, as Managing Director, and Gain Therapeutics, Inc., as Independent Director from 2021.
Dr. Melincoff also formerly worked at Naurex, Inc., as Director, ArmaGen, Inc., as Director, Photocure ASA, as Independent Director from 2017 to 2020, DBV Technologies SA, as Director, Kamada Ltd., as Independent Director from 2017 to 2018, AM-Pharma BV, as Director, Enterome SA, as Director, PROMETHERA Biosciences SA, as Director, Tobira Therapeutics, Inc., as Independent Director from 2014 to 2016, Adolor Corp., as Vice President-Business Development from 1999 to 2004, Shire Plc, as Senior Vice President-Corporate Development, BTG International, Inc., as Vice President-Business Development from 2014 to 2016, and Shire Pharmaceuticals, Inc., as Senior Vice President-Business Development from 2004 to 2013.
Dr. Melincoff received her undergraduate degree from George Washington University and graduate degree from The Pennsylvania State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 26/03/2024 | 12,194 ( 0.04% ) | 473 371 $ | 30/03/2024 | |
GAIN THERAPEUTICS, INC.
0.12% | 22/06/2023 | 19,558 ( 0.12% ) | 73 734 $ | 30/03/2024 |
SOLENO THERAPEUTICS INC
0.00% | 25/05/2023 | 666 ( 0.00% ) | 28 505 $ | 30/03/2024 |
| 28/09/2023 | 0 ( -.--% ) | - $ | 30/03/2024 |
Gwen Melincoff active positions
| Companies | Position | Start |
|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Director/Board Member | 08/08/2017 |
| SOLENO THERAPEUTICS, INC. | Director/Board Member | 25/04/2019 |
| PROTALIX BIOTHERAPEUTICS, INC. | Director/Board Member | 30/11/2019 |
| GAIN THERAPEUTICS, INC. | Director/Board Member | 31/12/2020 |
Vodia Capital LLC
 Vodia Capital LLC Investment ManagersFinance Part of Robertson Stephens Wealth Management LLC, Vodia Capital LLC provides investment advisory services. The private company is based in Concord, MA. The company was founded by David B. Matias. David B. Matias has been the CEO since incorporation. Vodia Capital was acquired by Robertson Stephens Wealth Management LLC on December 13, 2022. | Corporate Officer/Principal | - |
Former positions of Gwen Melincoff
| Companies | Position | End |
|---|---|---|
| PHOTOCURE ASA | Director/Board Member | 09/06/2020 |
| KAMADA LTD. | Director/Board Member | 19/12/2018 |
| TOBIRA THERAPEUTICS INC | Director/Board Member | 30/10/2016 |
BTG International, Inc.
 BTG International, Inc. Investment ManagersFinance BTG International Inc. (BTG International) is a venture capital subsidiary of BTG Ltd founded in 1981. The firm is headquartered in West Conshohocken, Pennsylvania. | Corporate Officer/Principal | 31/08/2016 |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Gwen Melincoff
| George Washington University | Undergraduate Degree |
| The Pennsylvania State University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 7 |
|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| SOLENO THERAPEUTICS, INC. | Health Technology |
| PHOTOCURE ASA | Health Technology |
| DBV TECHNOLOGIES | Health Technology |
| KAMADA LTD. | Health Technology |
| PROTALIX BIOTHERAPEUTICS, INC. | Health Technology |
| GAIN THERAPEUTICS, INC. | Health Technology |
| Private companies | 11 |
|---|---|
Adolor Corp.
 Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Health Technology |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
BTG International, Inc.
BTG International, Inc. Investment ManagersFinance BTG International Inc. (BTG International) is a venture capital subsidiary of BTG Ltd founded in 1981. The firm is headquartered in West Conshohocken, Pennsylvania. | Finance |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Health Technology |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
Vodia Capital LLC
Vodia Capital LLC Investment ManagersFinance Part of Robertson Stephens Wealth Management LLC, Vodia Capital LLC provides investment advisory services. The private company is based in Concord, MA. The company was founded by David B. Matias. David B. Matias has been the CEO since incorporation. Vodia Capital was acquired by Robertson Stephens Wealth Management LLC on December 13, 2022. | Finance |
Tobira Therapeutics, Inc.
 Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on October 6, 2006 and is headquartered in Madison, NJ. | Health Technology |
- Stock Market
- Insiders
- Gwen Melincoff
